Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SVFC 6/13 - IntelliCell Receives US Patent for its Stem Cell Extraction Technology
NEW YORK, June 13, 2013 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announces that it has been notified by the US Patent office that
its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented method for deriving blood vessel originated
vascular cells from adipose (fat) tissue by use of ultrasonic cavitation has been made official. This technology involves an
innovative mechanical method for the separation of stromal vascular fraction cells from adipose (fat) tissue, without the use of enzymes. Vascular cells
derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic
procedures. Investors can access the published patent at the US Patent website by entering the patent # 8,440,440. Link to patent
website: http://patft.uspto.gov/netahtml/PTO/srchnum.htm
IntelliCell's Chairman and CEO, Dr. Steven Victor, stated "Our Company is very pleased to announce today that with the publishing of our patent,
our technology is now protected and we expect our international patent publication in a short time."
About IntelliCell BioSciences, Inc.
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative and preventative conditions
of disease states with high unmet clinical needs. The Company has several patent-pending applications including the patent that was recently published, an
industry unique method of obtaining autologous stromal vascular fraction cells (SVF) cells from the vasculature surrounding adipose tissue containing adult
stem cells and a robust population of regenerative healing cells. The Company is also pioneering the development of autologous and allogeneic cells from
living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the
treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics. The
Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into an
ambulatory surgery center.
Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project,"
"intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could,"
"would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking
statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results
may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions,
activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential
factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and
Exchange Commission.
Contacts:
Anna Rhodes, IntelliCell BioSciences, Inc. Phone: (646) 576-8710 ?
Email: arhodes@intellicellbiosciences.com
Melissa Diaz?, South Street Media, Inc. Phone: (917) 937-8968
Email: info@southstreetmedia.com
SOURCE IntelliCell BioSciences, Inc.
Copyright 2013 PR Newswire
SVFC 6/13 - IntelliCell Receives US Patent for its Stem Cell Extraction Technology
NEW YORK, June 13, 2013 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announces that it has been notified by the US Patent office that
its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented method for deriving blood vessel originated
vascular cells from adipose (fat) tissue by use of ultrasonic cavitation has been made official. This technology involves an
innovative mechanical method for the separation of stromal vascular fraction cells from adipose (fat) tissue, without the use of enzymes. Vascular cells
derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic
procedures. Investors can access the published patent at the US Patent website by entering the patent # 8,440,440. Link to patent
website: http://patft.uspto.gov/netahtml/PTO/srchnum.htm
IntelliCell's Chairman and CEO, Dr. Steven Victor, stated "Our Company is very pleased to announce today that with the publishing of our patent,
our technology is now protected and we expect our international patent publication in a short time."
About IntelliCell BioSciences, Inc.
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative and preventative conditions
of disease states with high unmet clinical needs. The Company has several patent-pending applications including the patent that was recently published, an
industry unique method of obtaining autologous stromal vascular fraction cells (SVF) cells from the vasculature surrounding adipose tissue containing adult
stem cells and a robust population of regenerative healing cells. The Company is also pioneering the development of autologous and allogeneic cells from
living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the
treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics. The
Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into an
ambulatory surgery center.
Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project,"
"intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could,"
"would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking
statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results
may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions,
activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential
factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and
Exchange Commission.
Contacts:
Anna Rhodes, IntelliCell BioSciences, Inc. Phone: (646) 576-8710 ?
Email: arhodes@intellicellbiosciences.com
Melissa Diaz?, South Street Media, Inc. Phone: (917) 937-8968
Email: info@southstreetmedia.com
SOURCE IntelliCell BioSciences, Inc.
Copyright 2013 PR Newswire
LOL. Well put. SVFC is not typical penny stock.
SVFC .10 isn't even a MAJOR resistance Geb. 200MA at .13!
If traders will raise their ask to .063 it'll blast off NOW!
Major NY Research Firm Sees SVFC as Best in Play for Stem Cell Treatment
Last Updated: July 08, 2013 - 9:00am EST
(NEW YORK)--Intellicell Biosciences, Inc. (OTC:SVFC), a developer of technology for the extraction of autologous stem cells for physicians in the area of
regenerative medicine, was was mentioned in stem cell sector research report issued out today by New York based Maxim Group.
In the report on the sector, Maxim Group's analyst commented, "The company has treated over 300 patients and in some cases with dramatic results. We went
so far as to review patients stories and case histories, publications and even met with the company’s attorneys (ex-FDA reviewers) to understand the
definitions of minimally manipulated and the legal guidelines by which the company’s process allows physicians to treat patients. We left believing that this
is the only company, at the moment that qualifies with a process that meets current guidelines.”
This is a major development as this highlights SVFC as one of the only stem cell companies in the United States cleared to treat patients.
Maxim Group is a large New York institutional brokerage firm with an impressive research and investment banking division. www.maximgrp.com
In addition, Ludlow Research, a small cap equity research firm had also issued a research opinion on SVFC regarding their treatment using stem cells. All this
news, and their recent US patent as sent the stock to the most active trading list.
Ludlow Research Highlights
- Unique Stem Cell Extraction Technology from Blood Vessels
- FDA Registered Facility in NYC
- One of few cGTP Cell Manufacturing Facilities in US
- Use of Ultrasonic Cavitation instead of Enzymes
- Patent for Stem Cell Extraction Process
- Appointment of Dr Zain Khalpey to Advisory Board
FDA Compliant Stem Cell Facility
In November 2012, the Company was notified according to the Federal Drug Administration (“FDA”) validation registration number 3009842420, that its new
facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products
(HCT/P’s), such as the IntelliCell autologous stromal vascular fraction cellular product.
IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation. This
technology is an innovative mechanical method for the separation of stromal vascular fraction without the use of enzymes. Ultrasonic cavitation is an
innovative mechanical method of separating SVFCs from fat tissue. Vascular cells derived by IntelliCell's proprietary method are potentially useful in
bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures.
Open House Tour Event
Very rarely do we get the chance to tour a companies operation facilities. Since based in midtown Manhattan we had the chance to tour SVFC medical treatment
facilities, and can say first hand that their facilities were very impressive. Not only were their people visiting for basic cosmetic treatments, which the
company uses to generate revenue and offset operational costs, but the back-side treatment facilities were quit large and impressive. There were a number of
completed clean and professional minimal surgical treatment rooms, offices, and very impressive and FDA compliant stem cell extraction processing room, which
was managed by very experienced and professional personal.
The Company is working on conducting an open house event where shareholders, and institutional investors will be invited to tour their facilities on Park
Avenue, and meet the executives from IntelliCell. An announcement of this upcoming open house could be released in the coming days, and to potentially attend
this event in NYC you can register here to request more information.
All in all, SVFC isn't one of your regular penny stock, or run of the mill R&D stem cell stocks. SVFC has a very impressive treatment facility that will not
only manufacture stem cells through their now patented process, but treat patients as well. This places SVFC as one of the very few stem cell treatment and
manufacturers in the US, and they are always open to provide guided tours if you ever find yourself in New York City. This is defiantly one to watch.
$SVFC MERCK, ROCHE, PRO SPORTS, HUGE!: Board of Directors and Advisors___>
Company Web Site:
http://www.intellicellbiosciences.com/corporate-profile.html
Board of Directors
Leonard Mazur, COO Triax, Interim COO of IntelliCell BioSciences
Steven Victor MD
Myron Holubiak, Director, Chair of the Nominating and Governance Committee
Myron Holubiak is currently President of 1-800-Doctors, Inc. Mr. Holubiak is also Chairman of the Board of Directors of BioScrip, Inc., an infusion and home
health company, and Lead Independent Director of Ventrus BioSciences, Inc. From 1998 through 2001, Mr. Holubiak was President of Roche
Laboratories, Inc. and previously in his career, he co-founded and served as CEO to Emron, Inc, a strategic marketing firm serving the
pharmaceutical industry, which was acquired by Dunn & Bradstreet and IMS Health in 1995. Mr. Holubiak also currently serves on the Board of Trustees for the
Academy of Managed Care Foundation.
He was the head of a company with revenues of over $2.8 billion and he's on our small board of directors! More on Myron
Holubiak/Roche Labs HERE: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89213849
Michael J. Hershman
Mr. Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security. President and
CEO of the Fairfax Group, a company he founded in 1983, that has been retained by governments, corporations, law firms and international financial
institutions to assist on matters relating to the consult of senior-level officials and/or the entities with which they do business.
Medical Board of Advisors
Dr. James Andrews, The Andrews Institute, Washington Redskins
( http://www.cbssports.com/nfl/blog/eye-on-football/21937322/dr-james-andrews-calls-robert-griffin-iiis-recovery-superhuman )
Dr. Harold Bafitis, The Plastic Surgery Institute of The Palm Beaches
Dr. Peter Bruno, Internist, New York City
Dr. Greg Cavaliere, Orthopedic Surgeon, NY Rangers
Dr. Gil Chimes DC, DICBN, CCSP, CSCS Greenwich Sports Medicine in Greenwich, CT
Dr. Sydney Coleman, Tribeca Plastic Surgery, New York City
Dr. Mathew Cooper Aventura Chiropractor, Aventura, FL
Dr. Alberto Goldman, Plastic Surgeon, Brazil
Dr. Joshua Hackel, The Andrews Institute
Dr. Anthony V. Maddalo, Orthopedic Surgeon, NY Rangers
Dr. Frederick Nicola, D.I.S.C. Sports & Spine Center, Marian del Rey, Oakland/LA Raiders
Dr. Eric Richter, Neurologist, Chief LSU Health Sciences Center
Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore (MERCK SUB)
Dr. Nicholas Toscano, Periodontist, Editor in Chief JIAD
Mr. Kevin Wilk, PT, DPT The Andrews Institute
$SVFC MERCK, ROCHE, PRO SPORTS, HUGE!: Board of Directors and Advisors___>
Company Web Site:
http://www.intellicellbiosciences.com/corporate-profile.html
Board of Directors
Leonard Mazur, COO Triax, Interim COO of IntelliCell BioSciences
Steven Victor MD
Myron Holubiak, Director, Chair of the Nominating and Governance Committee
Myron Holubiak is currently President of 1-800-Doctors, Inc. Mr. Holubiak is also Chairman of the Board of Directors of BioScrip, Inc., an infusion and home
health company, and Lead Independent Director of Ventrus BioSciences, Inc. From 1998 through 2001, Mr. Holubiak was President of Roche
Laboratories, Inc. and previously in his career, he co-founded and served as CEO to Emron, Inc, a strategic marketing firm serving the
pharmaceutical industry, which was acquired by Dunn & Bradstreet and IMS Health in 1995. Mr. Holubiak also currently serves on the Board of Trustees for the
Academy of Managed Care Foundation.
He was the head of a company with revenues of over $2.8 billion and he's on our small board of directors! More on Myron
Holubiak/Roche Labs HERE: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89213849
Michael J. Hershman
Mr. Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security. President and
CEO of the Fairfax Group, a company he founded in 1983, that has been retained by governments, corporations, law firms and international financial
institutions to assist on matters relating to the consult of senior-level officials and/or the entities with which they do business.
Medical Board of Advisors
Dr. James Andrews, The Andrews Institute, Washington Redskins
( http://www.cbssports.com/nfl/blog/eye-on-football/21937322/dr-james-andrews-calls-robert-griffin-iiis-recovery-superhuman )
Dr. Harold Bafitis, The Plastic Surgery Institute of The Palm Beaches
Dr. Peter Bruno, Internist, New York City
Dr. Greg Cavaliere, Orthopedic Surgeon, NY Rangers
Dr. Gil Chimes DC, DICBN, CCSP, CSCS Greenwich Sports Medicine in Greenwich, CT
Dr. Sydney Coleman, Tribeca Plastic Surgery, New York City
Dr. Mathew Cooper Aventura Chiropractor, Aventura, FL
Dr. Alberto Goldman, Plastic Surgeon, Brazil
Dr. Joshua Hackel, The Andrews Institute
Dr. Anthony V. Maddalo, Orthopedic Surgeon, NY Rangers
Dr. Frederick Nicola, D.I.S.C. Sports & Spine Center, Marian del Rey, Oakland/LA Raiders
Dr. Eric Richter, Neurologist, Chief LSU Health Sciences Center
Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore (MERCK SUB)
Dr. Nicholas Toscano, Periodontist, Editor in Chief JIAD
Mr. Kevin Wilk, PT, DPT The Andrews Institute
SVFC..the beauteous playa of 2013, YES!
BOOOM! Breakout time. SVFCeeeeeeeeeeeeeeeeeeeeeeeeeeee
Wow! SVFC looking like a coiled spring on L2!
ZERO Volume today?! SHEESH! UBQU
MAXIM GROUP - NOT a 1 man operation:______>
http://www.maximgrp.com/about/team/
http://www.insideview.com/directory/maxim-group-llc
SVFC News: http://www.otcmarkets.com/news/otc-market-headline?id=15261281
ACCESS TO THE MAXIM GROUP $SVFC REPORT:
http://www.filesanywhere.com
LOGIN WITH:
User: Victor07
Password: Anna249249
SVFC with HUGE Biotechs in MAXIM GROUP REPORT:
Companies mentioned include:
Athersys, Inc. (ATHX) – $1.68 – Buy
Baxter (BAX) – $69.88 – NR
Capricor (private)
Cardio3 Biosciences (private)
Cytomedix (CMXI) – $0.42 – NR
Cytori Therapeutics (CYTX) – $2.43 – Buy
Dendreon (DNDN) – $4.48 – Sell
IntellicellBioScience (SVFC)-$0.05 - NR
Lonza (LONN.VX) – CHF72.30 -NR
Mesoblast Ltd. (MBLTY) – $25.14 – Buy
NeoStem, Inc. (NBS) – $0.57– NR
Osiris (OSIR) – $10.40 – NR
Pfizer (PFE) – $27.97 – NR
Pluristem (PSTI) – $2.98 – Hold
Teva Pharmaceuticals (TEVA) – $38.94 – Buy
*Closing prices (7/05/2013)
EXCELLENT post Nad. BIG reason I'm HOLDING ALL! $SVFC
Yeppers Woody. Those long tails mean dips are being LOADED. $SVFC
"Very rarely do we get the chance to tour a companies operation facilities. Since based in midtown Manhattan we had the chance to tour SVFC medical treatment"
$SVFC!
SOURCE:
http://www.wallstreetnewscast.com/profile/svfc.html
Very rarely do we get the chance to tour a companies operation facilities. Since based in midtown Manhattan we had the chance to tour SVFC medical treatment facilities, and can say first hand that their facilities were very impressive. Not only were their people visiting for basic cosmetic treatments, which the company uses to generate revenue and offset operational costs, but the back-side treatment facilities were quit large and impressive. There were a number of completed clean and professional minimal surgical treatment rooms, offices, and very impressive and FDA compliant stem cell extraction processing room, which was managed by very experienced and professional personal.
The Company is working on conducting an open house event where shareholders, and institutional investors will be invited to tour their facilities on Park Avenue, and meet the executives from IntelliCell. An announcement of this upcoming open house could be released in the coming days, and to potentially attend this event in NYC you can register here to request more information.
All in all, SVFC isn't one of your regular penny stock, or run of the mill R&D stem cell stocks. SVFC has a very impressive treatment facility that will not only manufacture stem cells through their now patented process, but treat patients as well. This places SVFC as one of the very few stem cell treatment and
manufacturers in the US, and they are always open to provide guided tours if you ever find yourself in New York City. This is defiantly one to watch.
$SVFC with HUGE Biotechs in the REPORT:
News: http://www.otcmarkets.com/news/otc-market-headline?id=15261281
http://www.filesanywhere.com
LOGIN WITH:
User: Victor07
Password: Anna249249
Companies mentioned include:
Athersys, Inc. (ATHX) – $1.68 – Buy
Baxter (BAX) – $69.88 – NR
Capricor (private)
Cardio3 Biosciences (private)
Cytomedix (CMXI) – $0.42 – NR
Cytori Therapeutics (CYTX) – $2.43 – Buy
Dendreon (DNDN) – $4.48 – Sell
IntellicellBioScience (SVFC)-$0.05 - NR
Lonza (LONN.VX) – CHF72.30 -NR
Mesoblast Ltd. (MBLTY) – $25.14 – Buy
NeoStem, Inc. (NBS) – $0.57– NR
Osiris (OSIR) – $10.40 – NR
Pfizer (PFE) – $27.97 – NR
Pluristem (PSTI) – $2.98 – Hold
Teva Pharmaceuticals (TEVA) – $38.94 – Buy
*Closing prices (7/05/2013)
$SVFC with HUGE Biotechs in MAXIM GROUP REPORT:
News: http://www.otcmarkets.com/news/otc-market-headline?id=15261281
http://www.filesanywhere.com
LOGIN WITH:
User: Victor07
Password: Anna249249
Companies mentioned include:
Athersys, Inc. (ATHX) – $1.68 – Buy
Baxter (BAX) – $69.88 – NR
Capricor (private)
Cardio3 Biosciences (private)
Cytomedix (CMXI) – $0.42 – NR
Cytori Therapeutics (CYTX) – $2.43 – Buy
Dendreon (DNDN) – $4.48 – Sell
IntellicellBioScience (SVFC)-$0.05 - NR
Lonza (LONN.VX) – CHF72.30 -NR
Mesoblast Ltd. (MBLTY) – $25.14 – Buy
NeoStem, Inc. (NBS) – $0.57– NR
Osiris (OSIR) – $10.40 – NR
Pfizer (PFE) – $27.97 – NR
Pluristem (PSTI) – $2.98 – Hold
Teva Pharmaceuticals (TEVA) – $38.94 – Buy
*Closing prices (7/05/2013)
ACCESS TO THE MAXIM GROUP REPORT:
SVFC with HUGE Biotechs in MAXIM GROUP REPORT:
News: http://www.otcmarkets.com/news/otc-market-headline?id=15261281
http://www.filesanywhere.com
LOGIN WITH:
User: Victor07
Password: Anna249249
Companies mentioned include:
Athersys, Inc. (ATHX) – $1.68 – Buy
Baxter (BAX) – $69.88 – NR
Capricor (private)
Cardio3 Biosciences (private)
Cytomedix (CMXI) – $0.42 – NR
Cytori Therapeutics (CYTX) – $2.43 – Buy
Dendreon (DNDN) – $4.48 – Sell
IntellicellBioScience (SVFC)-$0.05 - NR
Lonza (LONN.VX) – CHF72.30 -NR
Mesoblast Ltd. (MBLTY) – $25.14 – Buy
NeoStem, Inc. (NBS) – $0.57– NR
Osiris (OSIR) – $10.40 – NR
Pfizer (PFE) – $27.97 – NR
Pluristem (PSTI) – $2.98 – Hold
Teva Pharmaceuticals (TEVA) – $38.94 – Buy
*Closing prices (7/05/2013)
Major NY Research Firm Sees SVFC as Best in Play for Stem Cell Treatment
Last Updated: July 08, 2013 - 9:00am EST
(NEW YORK)--Intellicell Biosciences, Inc. (OTC:SVFC), a developer of technology for the extraction of autologous stem cells for physicians in the area of
regenerative medicine, was was mentioned in stem cell sector research report issued out today by New York based Maxim Group.
In the report on the sector, Maxim Group's analyst commented, "The company has treated over 300 patients and in some cases with dramatic results. We went
so far as to review patients stories and case histories, publications and even met with the company’s attorneys (ex-FDA reviewers) to understand the
definitions of minimally manipulated and the legal guidelines by which the company’s process allows physicians to treat patients. We left believing that this
is the only company, at the moment that qualifies with a process that meets current guidelines.”
This is a major development as this highlights SVFC as one of the only stem cell companies in the United States cleared to treat patients.
Maxim Group is a large New York institutional brokerage firm with an impressive research and investment banking division. www.maximgrp.com
In addition, Ludlow Research, a small cap equity research firm had also issued a research opinion on SVFC regarding their treatment using stem cells. All this
news, and their recent US patent as sent the stock to the most active trading list.
Ludlow Research Highlights
- Unique Stem Cell Extraction Technology from Blood Vessels
- FDA Registered Facility in NYC
- One of few cGTP Cell Manufacturing Facilities in US
- Use of Ultrasonic Cavitation instead of Enzymes
- Patent for Stem Cell Extraction Process
- Appointment of Dr Zain Khalpey to Advisory Board
FDA Compliant Stem Cell Facility
In November 2012, the Company was notified according to the Federal Drug Administration (“FDA”) validation registration number 3009842420, that its new
facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products
(HCT/P’s), such as the IntelliCell autologous stromal vascular fraction cellular product.
IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation. This
technology is an innovative mechanical method for the separation of stromal vascular fraction without the use of enzymes. Ultrasonic cavitation is an
innovative mechanical method of separating SVFCs from fat tissue. Vascular cells derived by IntelliCell's proprietary method are potentially useful in
bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures.
Open House Tour Event
Very rarely do we get the chance to tour a companies operation facilities. Since based in midtown Manhattan we had the chance to tour SVFC medical treatment
facilities, and can say first hand that their facilities were very impressive. Not only were their people visiting for basic cosmetic treatments, which the
company uses to generate revenue and offset operational costs, but the back-side treatment facilities were quit large and impressive. There were a number of
completed clean and professional minimal surgical treatment rooms, offices, and very impressive and FDA compliant stem cell extraction processing room, which
was managed by very experienced and professional personal.
The Company is working on conducting an open house event where shareholders, and institutional investors will be invited to tour their facilities on Park
Avenue, and meet the executives from IntelliCell. An announcement of this upcoming open house could be released in the coming days, and to potentially attend
this event in NYC you can register here to request more information.
All in all, SVFC isn't one of your regular penny stock, or run of the mill R&D stem cell stocks. SVFC has a very impressive treatment facility that will not
only manufacture stem cells through their now patented process, but treat patients as well. This places SVFC as one of the very few stem cell treatment and
manufacturers in the US, and they are always open to provide guided tours if you ever find yourself in New York City. This is defiantly one to watch.
Major NY Research Firm Sees SVFC as Best in Play for Stem Cell Treatment
Last Updated: July 08, 2013 - 9:00am EST
(NEW YORK)--Intellicell Biosciences, Inc. (OTC:SVFC), a developer of technology for the extraction of autologous stem cells for physicians in the area of
regenerative medicine, was was mentioned in stem cell sector research report issued out today by New York based Maxim Group.
In the report on the sector, Maxim Group's analyst commented, "The company has treated over 300 patients and in some cases with dramatic results. We went
so far as to review patients stories and case histories, publications and even met with the company’s attorneys (ex-FDA reviewers) to understand the
definitions of minimally manipulated and the legal guidelines by which the company’s process allows physicians to treat patients. We left believing that this
is the only company, at the moment that qualifies with a process that meets current guidelines.”
This is a major development as this highlights SVFC as one of the only stem cell companies in the United States cleared to treat patients.
Maxim Group is a large New York institutional brokerage firm with an impressive research and investment banking division. www.maximgrp.com
In addition, Ludlow Research, a small cap equity research firm had also issued a research opinion on SVFC regarding their treatment using stem cells. All this
news, and their recent US patent as sent the stock to the most active trading list.
Ludlow Research Highlights
- Unique Stem Cell Extraction Technology from Blood Vessels
- FDA Registered Facility in NYC
- One of few cGTP Cell Manufacturing Facilities in US
- Use of Ultrasonic Cavitation instead of Enzymes
- Patent for Stem Cell Extraction Process
- Appointment of Dr Zain Khalpey to Advisory Board
FDA Compliant Stem Cell Facility
In November 2012, the Company was notified according to the Federal Drug Administration (“FDA”) validation registration number 3009842420, that its new
facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products
(HCT/P’s), such as the IntelliCell autologous stromal vascular fraction cellular product.
IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation. This
technology is an innovative mechanical method for the separation of stromal vascular fraction without the use of enzymes. Ultrasonic cavitation is an
innovative mechanical method of separating SVFCs from fat tissue. Vascular cells derived by IntelliCell's proprietary method are potentially useful in
bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures.
Open House Tour Event
Very rarely do we get the chance to tour a companies operation facilities. Since based in midtown Manhattan we had the chance to tour SVFC medical treatment
facilities, and can say first hand that their facilities were very impressive. Not only were their people visiting for basic cosmetic treatments, which the
company uses to generate revenue and offset operational costs, but the back-side treatment facilities were quit large and impressive. There were a number of
completed clean and professional minimal surgical treatment rooms, offices, and very impressive and FDA compliant stem cell extraction processing room, which
was managed by very experienced and professional personal.
The Company is working on conducting an open house event where shareholders, and institutional investors will be invited to tour their facilities on Park
Avenue, and meet the executives from IntelliCell. An announcement of this upcoming open house could be released in the coming days, and to potentially attend
this event in NYC you can register here to request more information.
All in all, SVFC isn't one of your regular penny stock, or run of the mill R&D stem cell stocks. SVFC has a very impressive treatment facility that will not
only manufacture stem cells through their now patented process, but treat patients as well. This places SVFC as one of the very few stem cell treatment and
manufacturers in the US, and they are always open to provide guided tours if you ever find yourself in New York City. This is defiantly one to watch.
YEP! 6/13 - IntelliCell Receives US Patent for its Stem Cell Extraction Technology
NEW YORK, June 13, 2013 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announces that it has been notified by the US Patent office that
its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented method for deriving blood vessel originated
vascular cells from adipose (fat) tissue by use of ultrasonic cavitation has been made official. This technology involves an
innovative mechanical method for the separation of stromal vascular fraction cells from adipose (fat) tissue, without the use of enzymes. Vascular cells
derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic
procedures. Investors can access the published patent at the US Patent website by entering the patent # 8,440,440. Link to patent
website: http://patft.uspto.gov/netahtml/PTO/srchnum.htm
IntelliCell's Chairman and CEO, Dr. Steven Victor, stated "Our Company is very pleased to announce today that with the publishing of our patent,
our technology is now protected and we expect our international patent publication in a short time."
About IntelliCell BioSciences, Inc.
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative and preventative conditions
of disease states with high unmet clinical needs. The Company has several patent-pending applications including the patent that was recently published, an
industry unique method of obtaining autologous stromal vascular fraction cells (SVF) cells from the vasculature surrounding adipose tissue containing adult
stem cells and a robust population of regenerative healing cells. The Company is also pioneering the development of autologous and allogeneic cells from
living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the
treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics. The
Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into an
ambulatory surgery center.
Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project,"
"intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could,"
"would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking
statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results
may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions,
activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential
factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and
Exchange Commission.
Contacts:
Anna Rhodes, IntelliCell BioSciences, Inc. Phone: (646) 576-8710 ?
Email: arhodes@intellicellbiosciences.com
Melissa Diaz?, South Street Media, Inc. Phone: (917) 937-8968
Email: info@southstreetmedia.com
SOURCE IntelliCell BioSciences, Inc.
Copyright 2013 PR Newswire
$SVFC MERCK, ROCHE, PRO SPORTS, HUGE!: Board of Directors and Advisors___>
Company Web Site:
http://www.intellicellbiosciences.com/corporate-profile.html
Board of Directors
Leonard Mazur, COO Triax, Interim COO of IntelliCell BioSciences
Steven Victor MD
Myron Holubiak, Director, Chair of the Nominating and Governance Committee
Myron Holubiak is currently President of 1-800-Doctors, Inc. Mr. Holubiak is also Chairman of the Board of Directors of BioScrip, Inc., an infusion and home health company, and Lead Independent Director of Ventrus BioSciences, Inc. From 1998 through 2001, Mr. Holubiak was President of Roche Laboratories, Inc. and previously in his career, he co-founded and served as CEO to Emron, Inc, a strategic marketing firm serving the pharmaceutical industry, which was acquired by Dunn & Bradstreet and IMS Health in 1995. Mr. Holubiak also currently serves on the Board of Trustees for the Academy of Managed Care Foundation.
He was the head of a company with revenues of over $2.8 billion and he's on our small board of directors! More on Myron Holubiak/Roche Labs HERE: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89213849
Michael J. Hershman
Mr. Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security. President and CEO of the Fairfax Group, a company he founded in 1983, that has been retained by governments, corporations, law firms and international financial institutions to assist on matters relating to the consult of senior-level officials and/or the entities with which they do business.
Medical Board of Advisors
Dr. James Andrews, The Andrews Institute, Washington Redskins
( http://www.cbssports.com/nfl/blog/eye-on-football/21937322/dr-james-andrews-calls-robert-griffin-iiis-recovery-superhuman )
Dr. Harold Bafitis, The Plastic Surgery Institute of The Palm Beaches
Dr. Peter Bruno, Internist, New York City
Dr. Greg Cavaliere, Orthopedic Surgeon, NY Rangers
Dr. Gil Chimes DC, DICBN, CCSP, CSCS Greenwich Sports Medicine in Greenwich, CT
Dr. Sydney Coleman, Tribeca Plastic Surgery, New York City
Dr. Mathew Cooper Aventura Chiropractor, Aventura, FL
Dr. Alberto Goldman, Plastic Surgeon, Brazil
Dr. Joshua Hackel, The Andrews Institute
Dr. Anthony V. Maddalo, Orthopedic Surgeon, NY Rangers
Dr. Frederick Nicola, D.I.S.C. Sports & Spine Center, Marian del Rey, Oakland/LA Raiders
Dr. Eric Richter, Neurologist, Chief LSU Health Sciences Center
Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore (MERCK SUB)
Dr. Nicholas Toscano, Periodontist, Editor in Chief JIAD
Mr. Kevin Wilk, PT, DPT The Andrews Institute
$SVFC MERCK, ROCHE, PRO SPORTS, HUGE!: Board of Directors and Advisors___>
Company Web Site:
http://www.intellicellbiosciences.com/corporate-profile.html
Board of Directors
Leonard Mazur, COO Triax, Interim COO of IntelliCell BioSciences
Steven Victor MD
Myron Holubiak, Director, Chair of the Nominating and Governance Committee
Myron Holubiak is currently President of 1-800-Doctors, Inc. Mr. Holubiak is also Chairman of the Board of Directors of BioScrip, Inc., an infusion and home health company, and Lead Independent Director of Ventrus BioSciences, Inc. From 1998 through 2001, Mr. Holubiak was President of Roche Laboratories, Inc. and previously in his career, he co-founded and served as CEO to Emron, Inc, a strategic marketing firm serving the pharmaceutical industry, which was acquired by Dunn & Bradstreet and IMS Health in 1995. Mr. Holubiak also currently serves on the Board of Trustees for the Academy of Managed Care Foundation.
He was the head of a company with revenues of over $2.8 billion and he's on our small board of directors! More on Myron Holubiak/Roche Labs HERE: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89213849
Michael J. Hershman
Mr. Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security. President and CEO of the Fairfax Group, a company he founded in 1983, that has been retained by governments, corporations, law firms and international financial institutions to assist on matters relating to the consult of senior-level officials and/or the entities with which they do business.
Medical Board of Advisors
Dr. James Andrews, The Andrews Institute, Washington Redskins
( http://www.cbssports.com/nfl/blog/eye-on-football/21937322/dr-james-andrews-calls-robert-griffin-iiis-recovery-superhuman )
Dr. Harold Bafitis, The Plastic Surgery Institute of The Palm Beaches
Dr. Peter Bruno, Internist, New York City
Dr. Greg Cavaliere, Orthopedic Surgeon, NY Rangers
Dr. Gil Chimes DC, DICBN, CCSP, CSCS Greenwich Sports Medicine in Greenwich, CT
Dr. Sydney Coleman, Tribeca Plastic Surgery, New York City
Dr. Mathew Cooper Aventura Chiropractor, Aventura, FL
Dr. Alberto Goldman, Plastic Surgeon, Brazil
Dr. Joshua Hackel, The Andrews Institute
Dr. Anthony V. Maddalo, Orthopedic Surgeon, NY Rangers
Dr. Frederick Nicola, D.I.S.C. Sports & Spine Center, Marian del Rey, Oakland/LA Raiders
Dr. Eric Richter, Neurologist, Chief LSU Health Sciences Center
Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore (MERCK SUB)
Dr. Nicholas Toscano, Periodontist, Editor in Chief JIAD
Mr. Kevin Wilk, PT, DPT The Andrews Institute
Good morning all. Yeah.. I've been meaning to ask that be changed. Nice!
Nice and bright green in the buzz cloud: http://investorshub.advfn.com/boards/tcloud2.aspx
#9 on most read boards!: http://investorshub.advfn.com/boards/most_read.aspx